News >

Selinexor Offers Patients New Path in Relapsed/Refractory Myeloma

Jessica Hergert
Published: Thursday, Feb 27, 2020

Robb S. Friedman, MD, hematologist and oncologist at Massachusetts General Hospital

Robb S. Friedman, MD

Despite some toxicity concerns, the approval of selinexor (Xpovio) is a significant breakthrough for the treatment of heavily pretreated patients with relapsed/refractory multiple myeloma, said Robb S. Friedman, MD. 

"We've developed a wonderful problem to have in multiple myeloma,” said Friedman, a hematologist and oncologist at Massachusetts General Hospital. “Our patients are living much longer with artful combinations of immunomodulatory drugs (IMiDs), proteasome inhibitors, and anti-CD38 agents. Unfortunately, patients will inevitably become refractory to all of these drugs."

In July 2019, the FDA granted an accelerated approval to selinexor for use in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥4 prior therapies and whose disease is refractory to ≥2 proteasome inhibitors, ≥2 iMIDs, and a CD38-targeted monoclonal antibody. 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication